Vicebio, a London-based biotech agency specialising within the growth of respiratory virus vaccines, has been acquired French pharma big Sanofi in a deal doubtlessly price over £1bn.
The Parisian group intends to develop the capabilities of its vaccine design and growth group by incorporating the British agency’s “molecular clamp” expertise, a course of that stabilises viral proteins of their native form, permitting type efficient immune system responses.
“We’re excited to hitch Sanofi”, stated Emmanuel Hanon, chief govt at Vicebio.
“Their world scale and deep experience in vaccine growth present the perfect surroundings to totally realise the potential of our progressive expertise. As a part of the Sanofi group, we look ahead to advancing our platform and pipeline to ship significant advantages for sufferers and public well being.”
Vicebio was based in 2019 and rapidly rose to prominence. In 2024, the group acquired a $100m Sequence B funding in a spherical that included TCGX and Goldman Sachs.
The agency shall be acquired for an upfront cost of $1.15bn (£850m) with potential milestone funds of as much as $450m (£332m) relying growth and regulatory achievements.
“Vicebio’s ‘molecular clamp’ expertise introduces a purposefully easy however considerate strategy to additional enhance vaccine designs at a time when respiratory viral infections proceed to affect thousands and thousands globally”, stated Jean-François Toussaint, world head of analysis and growth vaccines at Sanofi.
“This acquisition furthers Sanofi’s dedication to vaccine innovation with the potential to develop next-generation mixture vaccines that might present safety to older adults in opposition to a number of respiratory viruses with a single immunisation.”
Register for Free
Bookmark your favourite posts, get day by day updates, and revel in an ad-reduced expertise.
Have already got an account? Log in
